"Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis"

作者全名："Tian, Yan; Chen, Long; Shi, Yuan"

作者地址："[Tian, Yan; Chen, Long; Shi, Yuan] Chongqing Med Univ, Childrens Hosp, Dept Neonatol, Chongqing 400014, Peoples R China; [Tian, Yan; Chen, Long; Shi, Yuan] Natl Clin Res Ctr Child Hlth & Disorders, Chongqing 400014, Peoples R China; [Tian, Yan; Chen, Long; Shi, Yuan] Minist Educ, Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China; [Tian, Yan; Chen, Long; Shi, Yuan] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing 400014, Peoples R China; [Tian, Yan; Chen, Long; Shi, Yuan] Chongqing Key Lab Pediat, Chongqing 400014, Peoples R China"

通信作者："Shi, Y (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Neonatol, Chongqing 400014, Peoples R China.; Shi, Y (通讯作者)，Natl Clin Res Ctr Child Hlth & Disorders, Chongqing 400014, Peoples R China.; Shi, Y (通讯作者)，Minist Educ, Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China.; Shi, Y (通讯作者)，China Int Sci & Technol Cooperat Base Child Dev &, Chongqing 400014, Peoples R China.; Shi, Y (通讯作者)，Chongqing Key Lab Pediat, Chongqing 400014, Peoples R China."

来源：VACCINES

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000916201800001

JCR分区：Q1

影响因子：5.2

年份：2023

卷号：11

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：COVID-19 vaccine; SARS-CoV-2; children; adverse reactions; immunogenicity; efficacy; meta-analysis

摘要："Vaccination is one of the most effective measures for children as the epidemic progresses. However, there is a significant research gap in the meta-analysis of the COVID-19 vaccines for children younger than 18 years. This study is a comprehensive review of different COVID-19 vaccines. Published articles were retrieved from PubMed, Embase, and the Cochrane Library. Twelve randomized controlled trials (RCTs) of COVID-19 vaccines were included in the review until 21 October 2022. Most local and systemic adverse reactions were predominantly mild to moderate in severity and disappeared quickly after different types of vaccines. The subunit vaccine had the highest safety. The significant risk was lower in the subunit vaccine group after the initial (RR 1.66, 95% CI 1.26-2.17, p = 0.0003) and booster vaccination (RR 1.40, 95% CI 1.02-1.92, p = 0.04). Younger children had a more outstanding safety profile in the mRNA and inactivated vaccine groups. The humoral immune response was proportional to the number of doses in the inactivated and the adenovirus vaccine groups, and the strength of immunogenicity was negatively correlated with age in the inactivated vaccine. The mRNA and the subunit vaccines provided satisfactory prevention against COVID-19, especially seven days after the booster dose. However, more research and longer-term follow-up are needed to assess the duration of immune responses, efficacy, and safety."

基金机构：National Key Research and Development Program of China [2022YFC2704803]

基金资助正文：National Key Research and Development Program of China (2022YFC2704803).